24 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/johnson--johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-psych-congress-302285418.html
22 Jul 2024
// PRESS RELEASE
https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-seeks-U.S.-FDA-approval-of-SPRAVATO-esketamine-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression/default.aspx
12 Jun 2024
// ACCESSWIRE
20 May 2024
// CONTRACT PHARMA
https://www.contractpharma.com/contents/view_breaking-news/2024-05-20/johnson-amp-johnson-1q-results/?widget=listSection
08 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/10/08/2756367/0/en/New-Safety-Data-Suggests-SPRAVATO-Esketamine-Nasal-Spray-is-More-Tolerable-and-Effective-Compared-to-Quetiapine-Extended-Release-XR-in-Adults-with-Treatment-resistant-Major-Depress.html
25 Apr 2023
// FDA
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-esketamine-hydrochloride-49242.pdf
LOOKING FOR A SUPPLIER?